[CLSTR]
< Back to situation

[REVISION HISTORY]

Pharmaceutical manufacturing investment trends

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-12 00:32 UTC → 2026-08-14 10:31 UTC · added removed

Pharmaceutical companies are making significant investments in manufacturing infrastructure, with a notable focus on expanding capacity within the United States. Eli Lilly and Resilience announced a $750 million partnership to expand U.S. pharmaceutical manufacturing, specifically targeting the production of medicines for diabetes and obesity in the Cincinnati, Ohio region. This move is intended to strengthen domestic supply chains amid potential U.S. policy shifts regarding tariffs on branded drugs. In a subsequent development, Bristol Myers Squibb announced is also expanding its U.S. footprint with a $2.3 billion investment to build a large-scale 600,000-square-foot multi-modal manufacturing campus in Houston, Texas, for biologics and small-molecule medicines. Located at Generation Park, the 600,000-square-foot Park in Houston, Texas. The facility will use utilize a modular design to produce various biologics, small-molecule medicines, including and antibody-drug conjugates. conjugates, allowing for future reconfiguration to meet evolving scientific needs. The project is expected to create approximately 500 permanent skilled jobs and 2,000 construction-related positions between 2027 and 2030, contributing to 2030. This initiative aligns with the company’s broader $40 billion commitment to expand domestic manufacturing and research in the U.S. While expanding in the U.S., Eli Lilly reported scaling back a planned $2.5 billion project in Alzey, Germany, by 50 percent. The company attributed this reduction to German healthcare austerity measures, which it criticized as a “savings law” that undermines the country’s competitiveness for pharmaceutical investment. Despite the reduced scope and impact on the original goal of 1,000 jobs, Eli Lilly intends to proceed with the facility's opening, which is scheduled for late 2027.

Versions

  1. 2026-08-14 10:31 UTC Pharmaceutical manufacturing investment trends
  2. 2026-08-12 00:32 UTC Pharmaceutical manufacturing investment trends
  3. 2026-08-10 19:05 UTC Pharmaceutical manufacturing investment trends

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.